Davis Todd C, CEO of Ligand Pharmaceuticals ($LGND), made three open market purchases of company shares in the past year, totaling about $1 million. His latest buy occurred on May 9, 2025. Among nearly 5,000 insiders, his activity ranks 531st by purchase value, below the average of 1.5 million and 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 14, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Common Stock | 12900 | $0.00 | 1,515,817.0000 | 0 | 0.86% | 0.00% |
| July 2, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Common Stock | 19108 | $0.00 | 1,539,886.0000 | 6,103,813 | 1.26% | 0.31% |
| Nov. 13, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Common Stock | 4961 | $0.00 | 1,520,778.0000 | 0 | 0.33% | 0.00% |
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Common Stock | 10495 | $0.00 | 199,381.0000 | 20,629,000 | 5.56% | 0.05% |
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Employee Stock Option (right to buy) | 50058 | $0.00 | 50,058.0000 | 20,629,000 | 9999.99% | 0.24% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 2039 | $183.83 | 195,946.0000 | 20,629,000 | 1.03% | 0.01% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 15600 | $183.83 | 197,985.0000 | 20,629,000 | 7.30% | 0.08% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Common Stock | 20782 | $0.00 | 182,119.0000 | 20,629,000 | 12.88% | 0.10% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 8178 | $183.83 | 173,941.0000 | 20,629,000 | 4.49% | 0.04% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Common Stock | 39644 | $0.00 | 213,585.0000 | 20,629,000 | 22.79% | 0.19% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 2805 | $183.83 | 188,886.0000 | 20,629,000 | 1.46% | 0.01% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 4255 | $183.83 | 191,691.0000 | 20,629,000 | 2.17% | 0.02% |
| Dec. 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | G | Common Stock | 130 | $0.00 | 161,337.0000 | 20,629,000 | 0.08% | 0.00% |
| July 2, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Restricted Stock Units | 19108 | $0.00 | 36,969.0000 | 6,103,813 | 106.98% | 0.31% |
| July 2, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Stock Option | 58230 | $0.00 | 58,230.0000 | 6,103,813 | 9999.99% | 0.95% |
| July 1, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | J | Series A Convertible Preferred Stock | 31279 | $0.00 | 3,127,868.0000 | 6,103,813 | 1.01% | 0.51% |
| July 1, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | C | Series A Convertible Preferred Stock | 15000 | $0.00 | 3,000.0000 | 6,103,813 | 83.33% | 0.25% |
| July 1, 2025 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | C | Common Stock | 1500000 | $10.00 | 1,502,917.0000 | 6,103,813 | 9999.99% | 24.58% |
| June 30, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | J | Common Stock | 233 | $91.08 | 161,467.0000 | 18,290,000 | 0.14% | 0.00% |
| June 10, 2025 | PALVELLA THERAPEUTICS, INC. | $PVLA | Davis Todd C | Director | A | Non-Qualified Stock Option (right to buy) | 12350 | $0.00 | 12,350.0000 | 11,018,747 | 9999.99% | 0.11% |
| May 9, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | P | Common Stock | 1680 | $104.57 | 153,404.0000 | 18,290,000 | 1.11% | 0.01% |
| May 9, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | P | Common Stock | 5523 | $105.67 | 161,234.0000 | 18,290,000 | 3.55% | 0.03% |
| May 9, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | P | Common Stock | 2307 | $104.53 | 155,711.0000 | 18,290,000 | 1.50% | 0.01% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Employee Stock Option (right to buy) | 93476 | $0.00 | 93,476.0000 | 18,290,000 | 9999.99% | 0.51% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Common Stock | 21382 | $0.00 | 151,724.0000 | 18,290,000 | 16.40% | 0.12% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | A | Common Stock | 20784 | $0.00 | 143,794.0000 | 18,290,000 | 16.90% | 0.11% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 4255 | $120.00 | 130,342.0000 | 18,290,000 | 3.16% | 0.02% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 6966 | $120.00 | 136,828.0000 | 18,290,000 | 4.84% | 0.04% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | F | Common Stock | 2231 | $120.00 | 134,597.0000 | 18,290,000 | 1.63% | 0.01% |
| Dec. 13, 2024 | PALVELLA THERAPEUTICS, INC. | $PVLA | Davis Todd C | Director | A | Stock Option (right to buy) | 24700 | $0.00 | 24,700.0000 | 0 | 9999.99% | 0.00% |
| Nov. 13, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Restricted Stock Units | 49605 | $0.00 | 263,306.0000 | 0 | 23.21% | 0.00% |
| Aug. 8, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | P | Common Stock | 2500 | $97.39 | 123,010.0000 | 17,757,000 | 2.07% | 0.01% |
| June 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | J | Common Stock | 350 | $60.71 | 120,510.0000 | 17,757,000 | 0.29% | 0.00% |
| June 14, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | A | Restricted Stock Units | 128977 | $0.00 | 213,701.0000 | 0 | 152.23% | 0.00% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Non-Qualified Stock Option (right to buy) | 7448 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.04% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Non-Qualified Stock Option (right to buy) | 2156 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.01% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Non-Qualified Stock Option (right to buy) | 2855 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.02% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Non-Qualified Stock Option (right to buy) | 3556 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.02% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Common Stock | 3556 | $66.19 | 120,160.0000 | 17,757,000 | 3.05% | 0.02% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Common Stock | 2156 | $68.51 | 116,604.0000 | 17,757,000 | 1.88% | 0.01% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Common Stock | 2855 | $67.24 | 114,448.0000 | 17,757,000 | 2.56% | 0.02% |
| March 25, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | Chief Executive Officer | M | Common Stock | 7448 | $46.20 | 111,593.0000 | 17,757,000 | 7.15% | 0.04% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | CHIEF EXECUTIVE OFFICER | A | Common Stock | 32436 | $0.00 | 104,145.0000 | 17,757,000 | 45.23% | 0.18% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | CHIEF EXECUTIVE OFFICER | A | Employee Stock Option (right to buy) | 131723 | $0.00 | 131,723.0000 | 17,757,000 | 9999.99% | 0.74% |
| Feb. 21, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | C | Secured Convertible Promissory Note | 175000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 21, 2024 | Pelthos Therapeutics Inc. | $PTHS | Davis Todd C | Director | M | Common Stock | 29167 | $4.80 | 29,167.0000 | 0 | 9999.99% | 0.00% |
| Feb. 15, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Davis Todd C | CHIEF EXECUTIVE OFFICER | F | Common Stock | 1381 | $74.65 | 71,709.0000 | 17,757,000 | 1.89% | 0.01% |